Utama › Fenilketonuria › Texas
Kajian klinikal Fenilketonuria di Texas
7 kajian untuk Fenilketonuria sedang mencari peserta di lokasi di Texas.
Bandar di Texas
Teks kajian rasmi (Bahasa Inggeris)
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
- University of Texas Southwestern Medical Center (UTSW), Dallas
Mengambil pesertaFasa 1
Umur 18 hingga 69 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07241234AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
- University or Texas, Southwestern medical Center, Dallas
Mengambil pesertaFasa 1/2
Umur 18 hingga 55 · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT06332807A Study of JNT-517 in Participants With Phenylketonuria (PKU)
- University of Texas Southwestern, Dallas
- University of Texas Health (UTHealth) Science Center at Houston, Houston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jul 2026 · NCT06971731Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
- UT Southwestern Medical Center, Dallas
Mengambil pesertaFasa 4
Umur 18 hingga 65 · Semua jantina · Dikemas kini 17 Jun 2026 · NCT07477691A Long-Term Study of JNT-517 in Participants With Phenylketonuria
- Children's Medical Center Dallas, Dallas
- University of Texas Southwestern Medical Center, Dallas
- University of Texas Health (UTHealth) Science Center at Houston, Houston
Mengambil pesertaFasa 3
Umur 4 ke atas · Semua jantina · Dikemas kini 1 Mei 2026 · NCT06628128A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
- University of Texas Southwestern Medical Center, Dallas
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 25 Mac 2026 · NCT05813678A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
- UT Southwestern Medical Center, Dallas
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 24 Mac 2026 · NCT06305234Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.